[
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
[og_img]
https://www.investing.com/news/press-releases/springworks-therapeutics-announces-expected-chmp-opinion-in-q2-2025-for-nirogacestat-for-the-treatment-of-adults-with-desmoid-tumors-in-the-european-union-93CH-4005999
Investing.com
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
Related articles
